Jessica Jensen

Chief Tech/Sci/R&D Officer bij POINT Biopharma, Inc. (United States)

44 jaar

Health Technology

Consumer Services

Commercial Services

Momenteel actieve connecties

Naam	Geslacht	Leeftijd	Verwante bedrijven	Samenwerking
Joe McCann	M	47	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	5 jaar
Neil Fleshner	M	60	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	5 jaar
Allan Silber	M	75	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	5 jaar
Ari Shomair	M	-	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	-
William Demers	M	66	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	4 jaar
Gerald Hogue	M	66	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	4 jaar
Justyna Kelly	F	39	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	3 jaar
David Mims	M	60	PROGENICS PHARMACEUTICALS, INC.	5 jaar
Jonathan Goodman	M	56	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	4 jaar
Margaret Gilmour	F	64	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	4 jaar
Philip Johnson	M	59	POIT BIOP	1 jaar
Michael Gottlieb	M	45	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	4 jaar
Michael Thompson	M	-	POIT BIOP	1 jaar
Gerry Hogue	M	-	POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	-
Peggy Gilmour	F	-	POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	-
Howard M. Glase	M	-	POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	-
Gordon Brooks	M	-	POIT BIOP	1 jaar
Chris Anderson	M	-	POIT BIOP	1 jaar

Meer zien

Relatiegrafiek

Connectie in verschillende bedrijven

Oude connecties

Naam	Geslacht	Leeftijd	Verwante bedrijven	Samenwerking
Mark Robert Baker	M	69	PROGENICS PHARMACEUTICALS, INC.	14 jaar
Peter J. Crowley	M	65	PROGENICS PHARMACEUTICALS, INC.	10 jaar
Angelo William Lovallo	M	59	PROGENICS PHARMACEUTICALS, INC.	7 jaar
Nicole S. Williams	F	79	PROGENICS PHARMACEUTICALS, INC.	12 jaar
Patrick Fabbio	M	56	PROGENICS PHARMACEUTICALS, INC.	5 jaar
Rajesh K. Malik	M	65	POIT BIOP	2 jaar
Bridget Martell	M	58	POIT BIOP	-
Karen Ferrante	M	66	PROGENICS PHARMACEUTICALS, INC.	6 jaar
Bradley Campbell	M	48	PROGENICS PHARMACEUTICALS, INC.	4 jaar
Mary Heino	F	64	PROGENICS PHARMACEUTICALS, INC.	-
Yael Margolin	M	70	POIT BIOP	2 jaar
David Lubner	M	60	POIT BIOP	2 jaar
Ann MacDougall	F	70	PROGENICS PHARMACEUTICALS, INC.	1 jaar
Michael Kishbauch	M	75	PROGENICS PHARMACEUTICALS, INC.	6 jaar
Robert J. Israel	M	67	PROGENICS PHARMACEUTICALS, INC.	21 jaar
David Scheinberg	M	68	PROGENICS PHARMACEUTICALS, INC.	25 jaar
Jeffrey D. Summer	M	64	PROGENICS PHARMACEUTICALS, INC.	3 jaar
Robin Hallett	M	-	POIT BIOP	-
Thomas Strack	M	-	PROGENICS PHARMACEUTICALS, INC.	-
Sherin Al-Safadi	M	-	POIT BIOP	-
Myra Rosario Herrle	M	-	POIT BIOP	2 jaar
Syed Mahmood	M	-	PROGENICS PHARMACEUTICALS, INC.	-
Daniel Pearlstein	M	-	POIT BIOP	2 jaar
Aseem Anand	M	-	PROGENICS PHARMACEUTICALS, INC.	-
Chris Horvath	M	-	POIT BIOP	1 jaar
Donna Husack	F	-	POIT BIOP	3 jaar
Hagop Youssoufian	M	67	PROGENICS PHARMACEUTICALS, INC.	1 jaar
Bryce V. Tenbarge	M	51	PROGENICS PHARMACEUTICALS, INC.	-
Asha Das	M	59	PROGENICS PHARMACEUTICALS, INC.	-
Robert Marshall	M	57	PROGENICS PHARMACEUTICALS, INC.	-
Matthew Vincent	M	-	POIT BIOP	1 jaar
Heinz Christoph Mäusli	M	61	PROGENICS PHARMACEUTICALS, INC.	1 jaar
Gérard Ber	M	66	PROGENICS PHARMACEUTICALS, INC.	1 jaar
Nitya G. Ray	M	71	PROGENICS PHARMACEUTICALS, INC.	17 jaar
Sheldon Hirt	M	60	PROGENICS PHARMACEUTICALS, INC.	1 jaar
Eric Ende	M	55	PROGENICS PHARMACEUTICALS, INC.	1 jaar
Melita Sequeira	F	-	POIT BIOP	-

Statistieken

Land	Connecties	% van het totaal
Verenigde Staten	55	100.00%

Ouderdom van de connecties

Actief

Verleden

Man

Vrouw

Besturend

Uitvoerend

Oorsprong van de connecties

Beurs
Insiders
Jessica Jensen
Persoonlijk netwerk